The MedMemos Study: Promoting Adherence to Medications in Pediatric Bone Marrow Transplant Patients (MedMemos)
MedMemos: An Intervention to Promote Medication Adherence in Pediatric Allogenic Hematopoietic Stem Cell Transplantation
The goal of this clinical trial is to test the MedMemos Intervention with parents and children who have received a bone marrow transplant. The main study questions are:
- Is the MedMemos intervention acceptable to patients and families?
- Is the MedMemos intervention feasible for patients, families, and healthcare providers?
- Does MedMemos help patients and families take their medications better?
Participants will be asked to complete surveys, attend 4 intervention sessions, and use an electronic box or pill bottle to store their medications in.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Ahna LH Pai, PhD
- Telefonnummer: (614) 938-1601
- E-Mail: Ahna.Pai@nationwidechildrens.org
Studieren Sie die Kontaktsicherung
- Name: Sarah N Drake, MS
- Telefonnummer: (614) 259-7462
- E-Mail: sarah.drake2@nationwidechildrens.org
Studienorte
-
-
Ohio
-
Columbus, Ohio, Vereinigte Staaten, 43205
- Rekrutierung
- Nationwide Children's Hospital
-
Kontakt:
- Ahna LH Pai, PhD
- Telefonnummer: (614) 938-1601
- E-Mail: Ahna.Pai@nationwidechildrens.org
-
Kontakt:
- Sarah N Drake, MS
- Telefonnummer: (614) 259-7462
- E-Mail: sarah.drake2@nationwidechildrens.org
-
Hauptermittler:
- Ahna LH Pai, PhD
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Child had a Pediatric Allogeneic Hematopoietic Cell Transplant (PAHCT)
- Child is 0-12 years of age
- At the time of recruitment child is still in the hospital for PAHCT
- Child's primary caregiver is responsible for administering medical care and is willing to give consent to participate
- Child is prescribed an oral medication regimen at discharge
Exclusion Criteria:
- Caregiver does not speak English, Spanish, or Arabic
- Caregiver is not available to provide written permission for the child's participation
- EMR or medical team report of the caregiver's cognitive status precludes completion of questionnaires
- The child's medical status or condition precludes completion of the study questionnaires as determined by the physician or caregiver
- Caregiver is unwilling to store medication in an electronic monitor
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: MedMemos
This arm will provide participants with the MedMemos Intervention
|
MedMemos is a 4-session tailored adherence promotion intervention that will provide caregivers with a combination of tailored and standardized medication and adherence education videos and a "Medication Management Kit" that provides tailored strategies to target identified barriers to successful medication management.
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Intervention Acceptability
Zeitfenster: At the end of session 4 (An average of 14 days following the patient's hospital discharge, up to 28 days following discharge)
|
Intervention acceptability will be demonstrated by caregivers rating MedMemos a mean of ≥ 4 as measured on Acceptability of Intervention Measure, Feasibility of Intervention Measure, and Intervention Appropriateness Measure.
Each measure asks participants to rate statements on a scale of "Completely Disagree" to "Completely Agree" Higher scores indicate greater acceptability, feasibility, and appropriateness.
|
At the end of session 4 (An average of 14 days following the patient's hospital discharge, up to 28 days following discharge)
|
|
Intervention Feasibility - Percentage of patients who enroll out of those approached
Zeitfenster: Enrollment rate will be continually monitored throughout enrollment and final enrollment percentage will be calculated at the close of enrollment. Enrollment is estimated to end during Month 9 of Year 2.
|
Feasibility will be assessed by calculating enrollment rate (total number of patients enrolled / total number of patients approached).
Feasible enrollment will be achieved by enrolling 80% or more of eligible caregivers.
|
Enrollment rate will be continually monitored throughout enrollment and final enrollment percentage will be calculated at the close of enrollment. Enrollment is estimated to end during Month 9 of Year 2.
|
|
Intervention Feasibility - Percentage of intervention sessions and follow-ups completed by enrolled participants.
Zeitfenster: Completion rates will be calculated during the study in real time as part of study monitoring. Final study completion rates will be reported after the final follow-up is complete. Follow-ups are estimated to be complete Month 11 of Year 2.
|
Feasibility will be assessed by calculating the percentage of MedMemos sessions attended and the number of follow-up visits completed.
Feasibility will be achieved if 80% or more of MedMemos sessions are attended by participants and if 80% or more of follow-up visits are completed by participants.
|
Completion rates will be calculated during the study in real time as part of study monitoring. Final study completion rates will be reported after the final follow-up is complete. Follow-ups are estimated to be complete Month 11 of Year 2.
|
|
Intervention Feasibility - Percentage of the intervention protocol delivered by the interventionist.
Zeitfenster: Intervention fidelity will be monitored in real time to maintain adherence to the intervention protocol. Final intervention fidelity will be reported after the final MedMemos session is completed. Sessions are anticipated to end in Month 11 Year 2.
|
Feasibility of the intervention delivery will be assessed by calculating the intervention fidelity.
Fidelity will be assessed by a member of the lab not involved in intervention delivery using a fidelity checklist developed by the study Principal Investigator.
Feasibility of the intervention delivery will be achieved if fidelity checklist scores are 80% are greater (80% or more of the intervention delivered across the study)
|
Intervention fidelity will be monitored in real time to maintain adherence to the intervention protocol. Final intervention fidelity will be reported after the final MedMemos session is completed. Sessions are anticipated to end in Month 11 Year 2.
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Adherence to immunosuppressant medication as assessed by electronic monitor
Zeitfenster: Daily adherence will be monitored for each patient after discharge through the 3-month follow-up.
|
To establish proof-of-concept adherence to immunosuppressants will be monitored for all patients.
Proof-of-concept will be established if ≥75% children take ≥75% of their immunosuppressant medication doses at all follow-up time points as measured by electronic monitor.
|
Daily adherence will be monitored for each patient after discharge through the 3-month follow-up.
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Hämatologische Erkrankungen
- Erkrankungen des Knochenmarks
- Verhalten
- Hämische und lymphatische Krankheiten
- Therapietreue und Compliance
- Gesundheitsverhalten
- Zuverlässigkeit des Patienten
- Patientenakzeptanz der Gesundheitsversorgung
- Störungen des Knochenmarkversagens
- Neubildungen
- Infektionen
- Medikamentenhaftung
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- STUDY00004461
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .